Spirulina and the PPAR Nuclear Receptor Family.

PPAR Isoforms: Structure, Ligands, and DNA Binding

The three peroxisome proliferator-activated receptor isoforms (PPAR-α/NR1C1, PPAR-δ/β/NR1C2, PPAR-γ/NR1C3) are ligand-activated nuclear receptors sharing the canonical nuclear receptor architecture: N-terminal ligand-independent AF-1 domain; central zinc-finger DBD (DNA-binding domain; two C4-type zinc fingers); hinge region; and C-terminal LBD (ligand-binding domain; 13 α-helices; ~1,300 ų hydrophobic pocket) containing the AF-2 helix-12 that repositions upon agonist binding to create a co-activator LXXLL interaction surface. PPARs obligatorily heterodimerise with RXR-α/β/γ (retinoid X receptor); the PPAR-RXR heterodimer binds PPRE (peroxisome proliferator response element; DR-1: 5′-AGGTCA-n-AGGTCA-3′) in promoters of target genes. In the unliganded state, PPARs recruit co-repressors (NCoR1, SMRT, HDAC3); ligand binding → co-repressor dissociation → co-activator recruitment (PGC-1α LXXLL, SRC-1, p300/CBP) → target gene transcription.

PPAR-α (liver, heart, kidney, skeletal muscle) responds to saturated/unsaturated fatty acids (palmitic acid Kd ~5–10 μM; oleic acid; arachidonic acid), eicosanoids (8S-HETE), and fibrate drugs (fenofibrate; gemfibrozil); drives FAO genes (CPT1A, ACSL1, ACADM, VLCAD, HADHB), ketogenesis (HMGCS2), lipoprotein metabolism (APOA1/2, LIPC), and FGF21. PPAR-γ (adipose, macrophages, colon) responds to PGs (15d-PGJ2; natural ligand), oxidised LDL components (9-HODE, 13-HODE), and thiazolidinediones (TZD; rosiglitazone, pioglitazone Kd ~4 nM); drives adipogenesis (FABP4/aP2, ADIPOQ, GLUT4, PEPCK), lipid droplet formation, and M2 macrophage polarisation (IL-10 ↑, HMOX1 ↑, CD36 ↑ in macrophages). PPAR-δ (ubiquitous, high in skeletal muscle, heart) responds to prostacyclin (PGI&sub2;), GW501516 (pharmacological), and saturated FA; drives mitochondrial biogenesis (PGC-1α → positive loop), glucose metabolism (PDK4 ↑, GLUT4 ↑), anti-inflammatory macrophage phenotype, and skeletal muscle oxidative fibre identity.

PGC-1α as PPAR Co-activator and Metabolic Integrator

PGC-1α (PPARGC1A) lacks intrinsic enzymatic activity but recruits histone acetyltransferases (p300/CBP) and the Mediator complex to PPAR-bound promoters via its LXXLL motifs (three: residues 92, 144, and 208). PGC-1α activity is controlled post-translationally: SIRT1 deacetylation (Lys13/14 and 10 other sites) activates; GCN5 acetyltransferase inactivates; AMPK phosphorylation (Thr177/Ser538) activates; CaMKIV Ser265 activates; p38 Ser265 activates in muscle; mTORC1/S6K1 Ser570 inhibitory phosphorylation; RIP140/NCoR suppress via competition. PGC-1α co-activates PPAR-α (FAO), ERRα/γ (mitochondrial biogenesis), NRF1/2 (mtDNA transcription), FOXO3a (antioxidant programme), and HNF4α (gluconeogenesis in fasting liver).

Spirulina’s Mechanistic Actions

• GLA/EPA → PPAR-α LBD ligands: Spirulina GLA (gamma-linolenic acid; ~0.5–1.5% of dry weight) is metabolised to DGLA and AA; DGLA and EPA (from GLA via Δ5-desaturase) bind PPAR-α LBD (Kd ~5–15 μM) → AF-2 helix-12 repositioning → PGC-1α LXXLL recruitment → CPT1A ↑ 20–30%, ACADM ↑ 15–25%, VLCAD ↑ 15–25%, HMGCS2 ↑ 10–20%; plasma TG ↓ 10–25% in RCTs.
• AMPK → SIRT1 → PGC-1α → PPAR-α co-activation ↑: AMPK Thr172 ↑ → NAD&sup+; ↑ → SIRT1 ↑ → PGC-1α deacetylation Lys13/14 → PPAR-α co-activation ↑ synergising with GLA ligand input; PPAR-α target gene mRNA (CPT1A, ACADM) ↑ 20–35%.
• Partial PPAR-γ modulation → insulin sensitisation: GLA/phycocyanin partial PPAR-γ agonism (low-affinity; full TZD-like effect absent) → GLUT4 Ser474 ↑ 15–25% in adipocytes, ADIPOQ ↑ 15–25%, RETN ↓ 15–25%, without full lipid droplet expansion (partial agonist profile: co-activator bias toward SRC-1 over p300); fasting insulin ↓ 10–20% in T2DM RCTs.
• PPAR-δ → skeletal muscle oxidative phenotype: PGI&sub2; (GLA→COX→PGI&sub2;) activates PPAR-δ LBD → PDK4 ↑, UCP3 ↑, GLUT4 ↑; mitochondrial content ↑ 10–20% (citrate synthase activity) in exercise-trained rodents receiving spirulina.
• NCoR/SMRT displacement: PCB-driven ROS ↓ reduces NCoR1 SUMOylation stabilisation → NCoR1 proteasomal turnover ↑ → PPAR-α/δ de-repression at FAO gene promoters.

Clinical Correlates and Dosing

Human RCTs (4–8 g/day, 8–12 weeks): TG ↓ 10–25%; LDL-C ↓ 8–15%; HDL-C ↑ 5–10% (PPAR-α/APOA1 induction); fasting glucose ↓ 5–15% (PPAR-γ insulin sensitisation); body fat % ↓ 2–4% in obese subjects (PPAR-α FAO + PPAR-γ partial agonism limiting lipogenesis). Animal data: PPAR-α target gene mRNA (CPT1A, ACADM) ↑ 20–35%; liver TG ↓ 20–35%; hepatic steatosis score ↓ in NAFLD models. Interactions: fibrates (PPAR-α full agonists) + spirulina — additive lipid lowering; monitor for rhabdomyolysis risk (theoretical). TZDs (PPAR-γ agonists) + spirulina — additive insulin sensitisation; monitor hypoglycaemia.